回春凉膈散이 db/db 마우스의 고혈당 및 지질대사에 미치는 효과 |
장수영, 정유선, 신현철 |
대구한의대학교 한의과대학 내과학교실 |
The Effects of Hoechunyanggyeok-san on hyperglycemia and
Dyslipidemia in db/db mice |
Soo-young Jang, Yu-sun Jung, Hyeon-cheol Shin |
Dept. of Internal Medicine of Korean Medicine, College of Korean Medicine, Dae-Gu Haany University |
Correspondence |
Hyeon-cheol Shin ,Tel: 054-281-0055, Fax: 054-281-7464, Email: ungaeshin@naver.com
|
|
Published online: March 30, 2014. |
|
|
ABSTRACT |
Objectives: Hoechunyanggyeok-san (HYS) is a traditional herbal medicine, which has been clinically used for treating febrile and inflammatory diseases. HYS has been reported to be a useful treatment for diabetes, atherosclerosis and hyperlipidemia in the type 1 diabetic model. However, the mechanism of the effects of HYS against hyperglycemia and hyperlipidemia is poorly understood. In the present study, we investigated the underlying mechanism of ameliorative effect of HYS on hyperglycemia and hyperlipidemia in vivo.
Methods : HYS (10, 50 mg/kg/day, p.o.) was administered every day for 2 weeks to db/db mice and its effect was compared with vehicle-treated db/db mice. To confirm serum glucose and triglyceride (TG) changes, serological testing was performed. The levels of sterol regulatory element-binding protein-1 (SREBP-1) activity and Sirtuin1 (SIRT1), AMP-activated protein kinase (AMPK), and acetyl-CoA carboxylase α (ACCα) expression were analyzed by western blot analysis.
Results: The administration of HYS significantly decreased the elevated serum glucose and TG in db/db mice. HYS administration increased the levels of SIRT1 and AMPK expression compared with the vehicle-treated group. Moreover, HYS treatment significantly inhibited SREBP-1 activity and ACCα expression in the liver, while the vehicle-treated group exhibited their increase.
Conclusions: In conclusion, HYS is suggested to have an improvement effect on hyperglycemia and hyperlipidemia by activating the SIRT1/AMPK signaling pathway and inhibiting SREBP-1. |
Key words:
Hoechunyanggyeok-san, hyperlipidemia, SIRT1, SREBP-1, ACCα |
|